Skip to main content

Clinical trial ANDROMEDA

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

Organ Amyloidose
Trial status Trial closed for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Janssen
EudraCT Identifier 2016-001737-27
Inclusion criteria - Histopathological diagnosis of amyloidosis- Measurable disease of amyloid light chain amyloidosis as defined by at least ONEof the following: serum M-protein ?0.5 g/dL by protein electrophoresis or serum free light chain ?50 mg/L- One or more organs
Last update